On October 29, Aurobindo Pharma announced that the company, in collaboration with Beijing Second Medicine Co., Ltd. (referred to as 'Second Medicine') and its wholly-owned subsidiary Xiamen Second BioTech Co., Ltd. (referred to as 'Second BioTech'), has obtained the 'Drug Clinical Trial Approval Notice' issued by the National Medical Products Administration for the new generation CAR-T drug ZM001 injection (referred to as 'ZM001') developed for the treatment of Systemic Lupus Erythematosus (SLE). This marks Aurobindo Pharma's official entry into the field of innovative biological drugs and a significant breakthrough in the field of CAR-T cell therapy for autoimmune diseases.
阳光诺和和艺妙神州合作开发的CAR-T疗法获准进入系统性红斑狼疮临床试验阶段
The CAR-T therapy developed through collaboration between Sunshine Theranostics and ArtMed Shenzhou has been approved to enter the clinical trial phase for systemic lupus erythematosus.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated